S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.

\*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.
Solid Tumor
DRUG: S095029|DRUG: S95029 and Sym021
Adverse Events (AEs) (Dose escalation part), Incidence, severity, and relationship of AEs, Through study completion, up to 2 years|Incidence of dose limiting toxicities (DLTs) (Dose escalation part), DLTs observed during a 28-day period, At the end of Cycle 1 (each cycle is 28 days)
Objective Response Rate, Through study completion, up to 2 years|Clinical Benefit Rate (CBR), Assessment based on complete response, partial response and stable disease â‰¥ 6 months, Through study completion, up to 2 years|Duration of response (DOR), Through study completion, up to 2 years|Progression Free Survival (PFS), Through study completion, up to 2 years|Overall Survival (OS), Through study completion, up to 2 years
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.

\*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.